Vivos Therapeutics (VVOS) Liabilities and Shareholders Equity (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $25.0 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 121.97% year-over-year to $25.0 million in Q1 2026; TTM through Mar 2026 was $101.9 million, a 76.39% increase from a year earlier, with the FY2025 full-year figure at $25.2 million, up 64.56% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $25.0 million, roughly flat from $25.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for VVOS reached as high as $29.6 million in Q1 2022 and fell as low as $10.3 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $18.2 million across 5 years, with a median of $15.8 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 59.27% in 2022 and soared 121.97% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $13.7 million in 2022, then decreased by 21.79% to $10.7 million in 2023, then jumped by 42.44% to $15.3 million in 2024, then surged by 64.56% to $25.2 million in 2025, then decreased by 0.43% to $25.0 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $25.0 million in Q1 2026, $25.2 million in Q4 2025, and $25.6 million in Q3 2025.